Engaging in data sharing, observational cohort research, and deeper analysis of available data to yield further insights can drive improved results for patients, making label and cohort extension ...

We read with interest the multinational drug use study by Yuanshi Jiao and colleagues.1 Although quantifying global access to WHO essential cancer medicines is valuable, the study's reliance on IQVIA ...

Analysis Group Announces Study Using Real-World Evidence to Support Blueprint Medicines' AYVAKYT® (avapritinib) Label Expansion for Advanced Systemic Mastocytosis in Europe ...

A collaborative effort between Guardant Health, Blueprint Medicines and Winship Cancer Institute, the study analyzed de-identified clinical and genomic data using the GuardantINFORM real-world ...

Together, these data support the company’s proposed Phase 3 registrational study regimen and its efforts to develop zorevunersen as a disease-modifying medicine for the treatment of Dravet syndrome.

Novo Nordisk’s Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis.